© PR Newswire
01.07.2025
CAMX
LISTED
STO
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
News Preview
First subcutaneous, once-monthly octreotide for treatment of acromegalyFor convenient self-administration with a pre-filled autoinjector penLUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the ma...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
CAMX
LISTED
STO
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
News Preview
First subcutaneous, once-monthly octreotide for treatment of acromegalyFor convenient self-administration with a pre-filled autoinjector penLUND, Sweden, July 1, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the ma...
Themefolio
Profiler
Peergroup
© PR Newswire
01.07.2025
VITR
LISTED
STO
Vitrolife Group completes refinancing facility backed by leading Nordic Banks
News Preview
GOTHENBURG, Sweden, July 1, 2025 /PRNewswire/ -- Vitrolife AB (publ) has today renewed and signed a loan agreement of EUR 300 million comprising of term loan and revolving credit facility. The term loan will be used to refinance existing debt and the revolving credit facility will be available for general corporate purposes.
The loan agreement...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
01.07.2025
TFX
LISTED
NYSE
Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business
News Preview
WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
01.07.2025
ATAI
LISTED
NASDAQ
atai Life Sciences Announces $50 Million Private Placement Financing
News Preview
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, in...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.07.2025
ATAI
LISTED
NASDAQ
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
News Preview
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage bio...
Themefolio
Profiler
Peergroup
© Newsfile
01.07.2025
COPN
LISTED
SIX
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
News Preview
Ad hoc announcement pursuant to Art. 53 LR Company sets ambitious vision for €480 million in recurring revenues and a 40% EBITDA margin by 2030; outlines roadmap for accelerated AI-driven growth and innovation.Dublin, Ireland--(Newsfile Corp. - July 1, 2025) - Cosmo N.V. (SIX: COPN), a global leader in AI-driven h...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
TEM
LISTED
NASDAQ
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualif...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
01.07.2025
AGFB
LISTED
EURONEXT
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
News Preview
AGFA HealthCare is proud to announce a landmark achievement: the adoption of its Enterprise Imaging Platform by the largest integrated health network in Latin America - and the fifth largest globally. MORTSEL, BE / ACCESS Newswire / July 1, 2025 / DASA (Diagnósticos da América S.A.) operates an extensive hospital network across Brazil and...
Themefolio
Profiler
Peergroup
© ActuNews
30.06.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 30 juni 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© ActuNews
30.06.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – June 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on June 26, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
NSIS B
LISTED
CPH
Transactions under Novonesis’ share buyback program
News Preview
Novonesis has now completed the announced share buyback program of B shares worth up to EUR 100 million (DKK 746 million) in total during 2025. As of June 27th, 2025, Novonesis has purchased an accumulated 1,729,099 shares with a transaction value of DKK 745,2 million under the share buyback program announced by Novonesis in Company announcement N...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Publishes Letter to Shareholders
News Preview
OSE Immunotherapeutics Publishes Letter to Shareholders...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
IBAB
LISTED
EURONEXT
IBA – Transparency Notification - Denominator
News Preview
June 30th, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
ZEAL
LISTED
CPH
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
News Preview
Company announcement – No. 16 / 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaning...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
GMAB
LISTED
CPH
Completion of Share Buy-back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
INDV
LISTED
NASDAQ
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
News Preview
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest U.S. stocks as of April...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
TEM
LISTED
NASDAQ
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
News Preview
Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due in 2030 (the “Notes”) in a private placement (the “Off...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
CELC
LISTED
NASDAQ
Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib
News Preview
• In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66%...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.06.2025
KDEV
LISTED
STO
Karolinska Development divests shares in portfolio company OssDsign
News Preview
STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. The divestments brings Karolinska Development a capital injection of approximately SEK 34.5 million....
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© PR Newswire
30.06.2025
HNSA
LISTED
STO
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
News Preview
LUND, Sweden, June 30, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), announced today the presentation of its five year extended pooled analysis including data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlif...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.06.2025
SN
LISTED
LSE
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
News Preview
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world’s oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew’s purpose of ‘Life Unlimited’ - making a diff...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
HIK
LISTED
LSE
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
News Preview
Next phase builds on 34+ years of serving the needs of US patients and healthcare providers
COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© PR Newswire
28.06.2025
SOBI
LISTED
STO
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
News Preview
Approval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment o...
Themefolio
Profiler
Peergroup
© BusinessWire
27.06.2025
TEM
LISTED
NASDAQ
Deadline Alert: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
News Preview
Glancy Prongay & Murray LLP reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
FYB
LISTED
XETR
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
News Preview
Press Release // 27. June 2025
Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed
Due to strong demand, the offering period for the public offering has been shortened and target volume was increased from initially EUR 50 million to EUR 70 million
Interest ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
FYB
LISTED
XETR
Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert
News Preview
Pressemitteilung // 27. Juni 2025
Formycon erhöht Anleihevolumen nach Überzeichnung – Anleihe 2025/2029 in Höhe von 70 Mio. Euro erfolgreich und vollständig platziert
Aufgrund starker Nachfrage Angebotszeitraum des öffentlichen Angebots verkürzt und Zielvolumen von ursprünglich 50 Mio. Euro auf 70 Mio. Euro erhöht
Zinssatz in Höhe des EURIBOR pl......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
FYB
LISTED
XETR
Formycon successfully places an EUR 70 million senior unsecured floating rate bond
News Preview
Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.06.2025
FYB
LISTED
XETR
Formycon platziert erfolgreich eine unbesicherte und variabel verzinsliche Anleihe in Höhe von EUR 70 Mio.
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014
NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© Globe Newswire
27.06.2025
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million
News Preview
STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidn...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
RAY B
LISTED
STO
RaySearch releases RayCare v2025
News Preview
STOCKHOLM, June 27, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the release of RayCare®* v2025, the latest version of its next-generation oncology information system. The new release delivers powerful functionality enhancements that streamline clinical workflows, improve data management, and strengthen interoperability across...
Themefolio
Profiler
Peergroup
© BusinessWire
26.06.2025
TEM
LISTED
NASDAQ
Deadline Approaching: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming August 12, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”).
IF YOU ARE AN INVESTOR WHO...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
BIOA B
LISTED
STO
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
News Preview
STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is pres...
Themefolio
Profiler
Peergroup
© PR Newswire
26.06.2025
BIOA B
LISTED
STO
BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize
News Preview
STOCKHOLM, June 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that BioArctic's founder, Professor Lars Lannfelt, will receive the 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering contributions to the understanding of Alzheimer's disease and to the development of the drug lecanemab. The prize is pres...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
FYB
LISTED
XETR
Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland
News Preview
Pressemitteilung // 26. Juni 2025
Teva wird Zweitvermarktungspartner für Formycons Stelara®-Biosimilar FYB202 (Ustekinumab) unter der Marke Fymskina® in Deutschland
Teva-Tochter Ratiopharm vermarktet Fymskina® als weiteres Formycon Ustekinumab-Biosimilar semi-exklusiv in Deutschland
Markteinführung von Fymskina® für das 3. Quartal 2025 gepl......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2025
FYB
LISTED
XETR
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
News Preview
Press Release // June 26, 2025
Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany
Teva's subsidiary Ratiopharm is going to commercialize Fymskina® as a second Formycon ustekinumab biosimilar on a semi-exclusive basis in Germany
Market launch of F......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2025
BAVA
LISTED
CPH
Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women
News Preview
COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
TEM
LISTED
NASDAQ
Ambry Genetics’ CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
News Preview
Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-reviewed study validating the accuracy of the Ambry CARE Program® (CARE) for hereditary cancer risk assessment has been published in the Journal of the National Comprehensive Cancer Network. T...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
DBV
LISTED
EURONEXT
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
News Preview
Châtillon, France, June 25, 2025...
Themefolio
Profiler
Peergroup
© ActuNews
25.06.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – June 25, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on June 23, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
25.06.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 25 juni 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transparanti...
Themefolio
Profiler
Peergroup
© PR Newswire
25.06.2025
HAMLET B
LISTED
STO
Hamlet BioPharma Holds Successful In Person Meeting with US FDA
News Preview
LUND, Sweden, June 25, 2025 /PRNewswire/ -- Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs for cancer and infections, today announces the successful first in-person meeting with the U.S. Food and Drug Administration (FDA). The meeting was held on June 24, 2025. The 'take home message' from the discussion wa...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
ERF
LISTED
EURONEXT
Eurofins Scientific: Director/PDMR Shareholding
News Preview
Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF T...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
AMRX
LISTED
NASDAQ
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
News Preview
Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
EVT
LISTED
XETR
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen
News Preview
NURTuRE-AKI ist eine neue Beobachtungsstudie, die longitudinale biologische Proben und klinische Daten von Patienten mit akutem Nierenversagen (Acute Kidney Injury, „AKI") sammelt. Sie wurde im Rahmen eines Forschungskonsortiums unter Leitung von Kidney Research UK entwickelt.
Die Studie konzentriert sich auf 3 Kohorten: AKI nach Herzop......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
EVT
LISTED
XETR
Evotec joins NURTuRE-AKI consortium to gain multi-omics-based molecular understanding of acute kidney injury
News Preview
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury (“AKI”) patients, developed as part of a research consortium led by Kidney Research UK
The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chr......
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2025
COPN
LISTED
SIX
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
News Preview
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
FYB
LISTED
XETR
US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada
News Preview
Pressemitteilung // 25. Juni 2025
US-Biosimilarspezialist Valorum Biologics LLC wird Kommerzialisierungspartner für Formycons Eylea®-Biosimilar FYB203/AHZANTIVE® (Aflibercept-mrbb) in den Vereinigten Staaten und Kanada
Valorum Biologics, US-Biosimilar-Spezialist mit Fokus auf Augenheilkunde und Onkologie wird FYB203/AHZANTIVE® exklusiv in den ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.06.2025
FYB
LISTED
XETR
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
News Preview
Press Release // June 25, 2025
U.S. biosimilar specialist Valorum Biologics LLC becomes commercialization partner for Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® (aflibercept-mrbb) in the United States and Canada
Valorum Biologics, an expert for ophthalmology and oncology biosimilars in the U.S. market, will exclusively commercialize FYB20......
Themefolio
Profiler
Peergroup
© Globe Newswire
25.06.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics provides an update on ongoing proceedings
News Preview
OSE Immunotherapeutics provides an update on ongoing proceedings...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.06.2025
EVT
LISTED
XETR
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
News Preview
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UKThe study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chroni...
Themefolio
Profiler
Peergroup
© PR Newswire
24.06.2025
INDV
LISTED
NASDAQ
Indivior Appoints Tony Kingsley to the Board of Directors
News Preview
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., wh...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
FYB
LISTED
XETR
Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist
News Preview
Pressemitteilung // 24. Juni 2025
Starke Nachfrage nach Formycon-Anleihe 2025/2029 führt zu Verkürzung der Angebotsfrist
Hohe Nachfrage institutioneller Investoren ermöglicht vorzeitiges Ende des öffentlichen Angebotszeitraums
Zeichnungsfrist über die Formycon-Webseite endet bereits am 26. Juni 2025, 23:59 Uhr MESZ
Zeichnung über DirectPlace de......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
FYB
LISTED
XETR
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
News Preview
Press Release // June 24, 2025
Strong demand for Formycon 2025/2029 Bond leads to early closing of subscription period
High demand by institutional investors enables early termination of public offering period
Subscription period via the Formycon website is now scheduled to end on 26 June 2025, at 11:59 p.m. CEST
Subscription via Deutsche B......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.06.2025
FYB
LISTED
XETR
Vorzeitiges Ende der Angebotsfrist für Anleihe aufgrund hoher Nachfrage
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014
NICHT ZUR VERBREITUNG, VERÖFFENTLICHUNG ODER WEITERGABE, DIREKT ODER INDIREKT, IN ODER INNERHALB DER VEREINIGTEN STAATEN VON AMERIKA, KANADA, AUSTRALIEN, JAPAN ODER ANDEREN LÄNDERN, IN DENEN DIE VERBREITUNG ODER VERÖFFENTLICHUNG RECHTSWIDRIG SEIN KÖNNTE. ES ......
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
TEM
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, inclusive (the “Class Perio...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
